文献速递食管胃疾病与幽门螺杆菌

幽门螺杆菌治疗的不良事件特征:Hp-EuReg 22000 例真实世界经验

Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
PubMed 文献 · Am J Gastroenterol · 2021-01-01

基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)22,492 例患者的真实世界数据,评估根除治疗不良事件(AE)的频率、类型、强度、持续时间及对依从性的影响。结果显示 23% 患者出现至少 1 种 AE,多数为轻度(57%),严重者仅 6%,严重不良事件 0.08%,平均持续 7 天;治疗依从率 97%,仅 1.3% 因 AE 停药。

要点

  • 含铋四联疗法耐受性最差,AE 发生率达 37%。
  • 最常见 AE 为味觉障碍(7%)、腹泻(7%)、恶心(6%)和腹痛(3%)。
  • AE 多为轻度且持续时间有限,对治疗依从性影响不显著。

核心结论

  • 幽门螺杆菌根除治疗常引起不良事件,但通常轻微且持续时间有限,对治疗依从性无显著干扰。

研究设计与样本

  • 欧洲 27 个国家、300 名研究者参与的前瞻性非干预性登记研究,纳入 22,492 例接受根除治疗的患者,记录所有处方方案及安全性数据,并进行质量控制。

主要发现

  • 不同治疗方案导致 23% 的病例出现至少 1 种不良事件,经典含铋四联疗法耐受性最差(37% 发生 AE)。
  • 最常见不良事件为味觉障碍(7%)、腹泻(7%)、恶心(6%)和腹痛(3%)。
  • 多数不良事件为轻度(57%),6% 为严重,仅 0.08% 为严重不良事件,平均持续 7 天。
  • 治疗依从率为 97%,仅 1.3% 的患者因不良事件中断治疗。
  • 在标准三联、伴同疗法、含铋四联及左氧氟沙星三联或四联方案中,较长疗程与不良事件发生率较高显著相关。

临床怎么用

  • 临床处方幽门螺杆菌根除方案时应告知患者可能出现的不良事件,但多数轻微且不影响完成治疗。
  • 含铋四联疗法不良事件发生率较高,选择方案时需权衡疗效与耐受性。
  • 较长疗程可能增加不良事件风险,应结合方案类型合理确定疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the "European Registry on Helicobacter pylori management." METHODS: Systematic prospective noninterventional registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H. pylori infection in routine clinical practice. All prescribed eradication treatments and their corresponding safety profile were recorded. AEs were classified depending on the intensity of symptoms as mild/moderate/severe and as serious AEs. All data were subject to quality control. RESULTS: The different treatments prescribed to 22,492 patients caused at least 1 AE in 23% of the cases; the classic bismuth-based quadruple therapy was the worst tolerated (37% of AEs). Taste disturbance (7%), diarrhea (7%), nausea (6%), and abdominal pain (3%) were the most frequent AEs. The majority of AEs were mild (57%), 6% were severe, and only 0.08% were serious, with an average duration of 7 days. The treatment compliance rate was 97%. Only 1.3% of the patients discontinued treatment due to AEs. Longer treatment durations were significantly associated with a higher incidence of AEs in standard triple, concomitant, bismuth quadruple, and levofloxacin triple or quadruple therapies. DISCUSSION: Helicobacter pylori eradication treatment frequently induces AEs, although they are usually mild and of limited duration. Their appearance does not interfere significantly with treatment compliance.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Nyssen OP, Perez-Aisa A, Tepes B, et al. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021. PMID: 33840725. doi:10.14309/ajg.0000000000001246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。